Y. Lee

发表

NC381, a Novel Anticancer Agent, Arrests the Cell Cycle in G0-G1 and Inhibits Lung Tumor Cell Growth in Vitro and in Vivo

M. Cao, Y. Lee, Ningping Feng, 2004, Journal of Pharmacology and Experimental Therapeutics.

A NOVEL ANTICANCER AGENT , ARRESTS THE CELL CYCLE IN G 0G 1 AND INHIBITS LUNG TUMOR CELL GROWTH IN VITRO AND IN VIVO

M. Cao, Y. Lee, Ningping Feng, 2003 .

GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.

V. Lam, Y. Lee, Ningping Feng, 2003, Cancer research.

Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin

Y. Lee, Ningping Feng, S. Viau, 2006, Anti-cancer drugs.

Feedback amplification of senolysis using caspase-3-cleavable peptide-doxorubicin conjugate and 2DG.

Seung Woo Chung, Y. Byun, Y. Lee, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Journal of Clinical Laboratory Analysis 19:182–188 (2005) Optimization of the PAXgene TM Blood RNA Extraction System for Gene Expression Analysis of Clinical Samples

Y. Lee, A. Vassilakos, Jim A. Wright, 2022 .

GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.

Y. Lee, Ningping Feng, S. Viau, 2009, International journal of oncology.

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.

Seung Woo Chung, Y. Byun, Y. Lee, 2022, Journal of controlled release : official journal of the Controlled Release Society.

GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.

Y. Lee, Ningping Feng, M. Wang, 2006, International journal of oncology.

Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2

Y. Lee, A. Vassilakos, Jim A. Wright, 2011, Cancer Chemotherapy and Pharmacology.

Potent antimicrobial activity of 3-(4,5-diaryl-1H-imidazol-2-yl)-1H-indole derivatives against methicillin-resistant Staphylococcus aureus.

Y. Lee, Raed A. Al‐Qawasmeh, Jim A. Wright, 2010, Bioorganic & medicinal chemistry letters.

RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo

Y. Lee, Ningping Feng, M. Wang, 2007, Anti-cancer drugs.

Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma.

In‐San Kim, Y. Lee, Gi-Hoon Nam, 2021, Cancer letters.

Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma.

M. Cao, Y. Lee, Ningping Feng, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A novel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis

Y. Lee, Raed A. Al‐Qawasmeh, S. Viau, 2009, Molecular Cancer Therapeutics.